Literature DB >> 30216543

Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.

Matthias Löhle1,2, Graziella Mangone3, Martin Wolz4, Bettina Beuthien-Baumann5,6,7, Liane Oehme5, Jörg van den Hoff6, Jörg Kotzerke5, Heinz Reichmann8, Jean-Christophe Corvol3, Alexander Storch1,2.   

Abstract

OBJECTIVE: The objective of this study was to evaluate the effects of common functional polymorphisms in genes involved in dopamine metabolism on striatal dopamine turnover in de novo Parkinson's disease (PD).
METHODS: This was an observer-blinded cohort study investigating effects of common functional polymorphisms in dopa decarboxylase (DDC, rs921451), monoamine oxidase B (MAOB; rs1799836), catechol-O-methyltransferase (COMT, rs4680), and dopamine transporter/solute carrier family 6 member 3 (DAT/SLC6A3, variable number tandem repeats) genes on 18 F-fluorodopa uptake and an effective distribution volume ratio (inverse of dopamine turnover) measured by 18 F-fluorodopa PET in 28 untreated PD patients.
RESULTS: Patients carrying the MAOBCC/(C)/CT genotype (low/intermediate enzyme activity) had a lower dopamine turnover in the putamen (higher mean effective distribution volume ratio) when compared with patients with MAOBTT/(T) genotype (high enzyme activity). Striatal PET measures were not different between variants in the remaining genes.
CONCLUSIONS: The MAOB (rs1799836) polymorphism predicts putaminal dopamine turnover in early PD with the MAOBTT allele linked to high enzyme activity leading to higher intrinsic dopamine turnover, which has been demonstrated to constitute a risk factor for motor complications.
© 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; dopamine metabolism; dopamine turnover; functional gene polymorphisms; monoamine oxidase B (MAOB); positron emission tomography (PET)

Mesh:

Substances:

Year:  2018        PMID: 30216543     DOI: 10.1002/mds.27466

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  4 in total

Review 1.  Psychosis in Parkinson's Disease: A Lesson from Genetics.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Sokratis G Papageorgiou; Chiara Villa
Journal:  Genes (Basel)       Date:  2022-06-20       Impact factor: 4.141

2.  Clinical and Clinical-Pharmacogenetic Models for Prediction of the Most Common Psychiatric Complications Due to Dopaminergic Treatment in Parkinson's Disease.

Authors:  Sara Redenšek; Barbara Jenko Bizjan; Maja Trošt; Vita Dolžan
Journal:  Int J Neuropsychopharmacol       Date:  2020-11-26       Impact factor: 5.176

3.  Functional MAOB Gene Intron 13 Polymorphism Predicts Dyskinesia in Parkinson's Disease.

Authors:  Matthias Löhle; Graziella Mangone; Wiebke Hermann; Denise Hausbrand; Martin Wolz; Julia Mende; Heinz Reichmann; Andreas Hermann; Jean-Christophe Corvol; Alexander Storch
Journal:  Parkinsons Dis       Date:  2022-01-20

4.  The Role of Single Nucleotide Polymorphisms of Monoamine Oxidase B, Dopamine D2 Receptor, and DOPA Decarboxylase Receptors Among Patients Treated for Parkinson's Disease.

Authors:  Barbara Zapała; Tomasz Stefura; Monika Piwowar; Sylwia Czekalska; Magdalena Zawada; Maria Hadasik; Bogdan Solnica; Monika Rudzińska-Bar
Journal:  J Mol Neurosci       Date:  2022-01-19       Impact factor: 3.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.